In this edition, Dr.  Margarida Manso (PT), associate member of the EAU Section of Female and Functional Urology (ESFFU), discusses female stress urinary incontinence (SUI). Dr. Manso details the physiological elements of SUI in regards to the bladder neck and urethra, as well as the urinary sphincter. The multiple causes behind SUI are outlined, including: ageing, radiotherapy trauma and neurological disease. Dr. Manso shares information on the different treatment options starting with conservative management (lifestyle interventions and PFMT), followed by vaginal devices and surgical interventions. Surgical interventions discussed include bulking agents, synthetic MUS, autologous fascial slings, colposuspension and external compression devices (such as ACT and AUS).Dr. Manso concludes with an update on vaginal lasers for SUI, which are currently not recommended as a treatment option. 

In this edition, Dr. Lazaros Tzelves (GR), a member of the EAU Guidelines Panel for non-neurogenic female LUTS, discusses underactive bladder (UAB) in women. Dr. Tzelves clinically defines what an underactive bladder is, followed by sharing information on its prevalence and aetiology.  UAB is difficult to diagnose and difficult to manage. Dr Tzelves discusses how urologists can diagnostically approach patients with suspected underactive bladder and what the options are for managing this condition conservatively. Lastly, Dr. Tzelves talks about when surgical treatment is useful, and what options exist. 

In this podcast, EAU Prostate Cancer Guidelines Panel members Prof. Nicolas Mottet (FR) and Prof. Philip Cornford (GB), have an in-depth discussion on active surveillance in prostate cancer. The two experts elaborate in detail on what active surveillance is, including the difference between active surveillance and watchful waiting, which can often be mis-understood.  Prof. Mottet and Prof. Cornford delve into the importance of maintaining quality of life and the fact that active surveillance does not mean no treatment but is considered if the patient will benefit from it. More information is shared on the guidelines for active surveillance in prostate cancer and how often to repeat biopsies, MRI and PSA testing. Also, vital information about who the good candidates for active surveillance are, such as Gleason 3+3, as well as candidates that it is not suitable for, and the exclusion criteria. Lastly, Prof. Mottet and Prof. Cornford discuss the problem of compliance and look at what data is currently available. 

In this edition, we have Dr. Maria Carmen Mir (ES), chief editor of the UROONCO RCC editorial board, together with Prof. Alessandro Antonelli (IT) from the University of Verona and director of the Department of Urology at Borgo Trento Hospital, talking about the retroperitoneal approach to robotic partial nephrectomy (RPN).Prof. Antonelli begins this interview with a review on transrectal and transperineal for retroperitoneal partial nephrectomy.  He shares his experience and expert-knowledge on the likelihood of conversion of surgical strategy. Dr. Mir and Prof. Antonelli conclude with a discussion on the X series systems from Intuitive and if they are mandatory for retro or not. This expert interview took place during ERUS22, in Barcelona.

In this edition, we have Dr. Riccardo Bertolo (IT), the associate editor of UROONCO RCC editorial board, together with Dr. Alberto Breda (ES), Head of the Oncology Urology Unit and Kidney Transplant Surgical Team Urology Department, Fundació Puigvert, Barcelona, and chairman of ERUS and president of the ERUS22 congress, talking about the novel alternative robotic platform that was recently launched in Europe.Dr. Riccardo Bertolo and Dr. Alberto Breda share highlights on their first experiences with the Hugo robot in performing partial nephrectomy. They discuss the docking/port placement and give details about the Da Vinci experience (S/Si) in regard to facilitating the landing with this new technology.They share views on the idea of whether or not the multi-carts Hugo robot will prevent the widespread diffusion of the retroperitoneal robotic approach to partial nephrectomy.

In this edition, Dr. Constance Thibault (FR), associate editor of the UROONCO PCa educational platform, discusses triplet therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In the last decade, the outcome of metastatic prostate cancer has been improved by intensifying the systemic therapy with the addition of docetaxel and/or new hormonal therapies. Clinicians now have several treatment options to offer their patients with mHSPC. This raises the issue of the optimal choice? Dr. Thibault answers questions about why triplet therapy (ADT + DOCETAXEL + NHT) is recommended to mHSPC patients, and do all patients benefit from a triplet therapy or only specific subgroups?Lastly, Dr. Thibault talks about which triplet therapy is recommended to use in clinical practice assuming that abiraterone and darolutamide are both approved in combination with ADT + DOCETAXEL for mHSPC patients. 

During this episode, Dr. Thomas Seisen (FR), an associate member on the EAU Guidelines Panel for Non-Muscle Invasive Bladder Cancer,  answers questions about metastatic upper urothelial cancer (UTUC) treatment options in the 2022 guidelines:What are the systemic treatment options for metastatic UTUC in the first-line setting?Can a maintenance systemic treatment be proposed to metastatic UTUC patients responding to first-line platinum-based chemotherapy?What are the systemic treatment options for metastatic UTUC in the second-line setting?What are the systemic treatment options for metastatic UTUC in the third-line setting?Is there a role for surgery in the management of metastatic UTUC?For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates.

In this edition, we have Dr. Teele Kuusk (UK), the associate editor of the UROONCO RCC educational platform discussing kidney cancer highlights at the recent ESMO2022. Dr. Kuusk begins with the reporting of several new trials and the accompanying results, which include: Phase 3 CheckMate-914, Phase 3 COSMIC-313, Phase 2 Keynote-B61, and Cohort 1 of LITESPARK-003 study. After delivering the trial results, Dr. Kuusk shares the possible reasons why the adjuvant trials failed. For more details on the results of the LITESPARK-003 study, you can watch this video  featuring Assoc. Prof. Jaime Merchan (US), who presented at ESMO2022. https://kidney.uroonco.uroweb.org/video/cohort-1-of-litespark-003/ This article was first posted on UROONCO.

In this podcast, members of the EAU Guidelines Panel for RCC Prof. Axel Bex (DE)  and Prof. Jens Bedke (DE), discuss renal cell carcinoma (RCC), with updates on treatments and current trials. Prof. Bex and Prof. Bedke talk about what's new in adjuvant treatment for patients with high-risk RCC after radical nephrectomy.  This follows with discussions on the combination and triplet trials, as well as the recent developments in the systemic treatment of advanced RCC.Other topics include cytoreductive surgery, metastasectomy, systemic therapy and observation.  Lastly, Prof. Axel and Prof. Bedke analyse what the role of Stereotactic Body Radiotherapy (SBRT) in advanced RCC might be.  

In this edition we have Dr. Benoît Peyronnet (FR), a Panel Member, and Dr. Néha Sihra (UK), an associate member of the EAU Guidelines Panel for female lower urinary tract symptoms, discussing overactive bladder syndrome (OAB) in women. Ms. Sihra answers questions about what to do when evaluating an overactive bladder patient. She covers the importance of clinical history, and which type of examinations to do, as well as giving details on bladder diaries and symptom scores. More details are given about specific dietary measures and conservative treatments for overactive bladder patients including fluid intake, weight and specific exercises.Ms. Sihra also talks about when to use, and more importantly, when not to use, various medications. And lastly, she looks at what the alternatives are for patients who fail first line treatments.